A Phase II Study of Modified Lenalidomide, Bortezomib and Dexamethasone for Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 01 Mar 2017
At a glance
- Drugs Bortezomib (Primary) ; Dexamethasone (Primary) ; Lenalidomide (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms RVD-Lite
- 17 Feb 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
- 17 Feb 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.
- 18 Jul 2016 Planned primary completion date changed from 1 Dec 2015 to 1 Dec 2016.